comprehensive -WSS

comprehensive

author：focus 2025-09-28 21:06:21 - browse：37261

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： 'Screen and refer' systems are hurting patients

knowledge

WSS

Lawmakers grill UnitedHealth CEO on Change cyberattack

Primary care doctor shortage won't be solved by free med school tuition

Prescription digital therapeutics are key to pharma’s future

Undocumented workers face uncertainty as immigration law takes effect in Florida

Canadians with cystic fibrosis outlive Americans by a decade

Drug cartel violence flares in western Mexico after vigilante leader's killing

focus

comprehensive

leisure time

Peter Hotez and the public health issue of online harassment

Black vets could get higher VA benefits if race not used in lung test

As demand for Covid shots wanes, Moderna seeks its next success

GSK’s asthma push continues as drug succeeds in Phase 3 trials

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Beware reading your test results before your doctor does

Medicare proposal to cover medical devices draws a mixed reaction

AltruBio raises $225 million to develop ulcerative colitis drug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Welsh Carson private equity firm escapes from FTC antitrust case

Wikipedia

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Hubble vs. James Webb telescope images: See the difference

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

UpToDate has a racism problem: Dr. Stanley Goldfarb

Dexcom's push to bring CGM to type 2 diabetes patients

leisure time

knowledge

explore

leisure time